Digoxin for patients with atrial fibrillation and heart failure: Paradise lost or not?

European Heart Journal

Volumn 34, Issue 20, 2013, Pages 1468-1470

  Van Veldhuisen, Dirk J ^a   Van Gelder, Isabelle C ^a   Ahmed, Ali ^b   Gheorghiade, Mihai ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; PLACEBO;

CARDIOVASCULAR MORTALITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; EXERCISE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HUMAN; INOTROPISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINUS RHYTHM; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DIGOXIN; FEMALE; HEART FAILURE; HUMANS; MALE;

EID: 84878323677     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs483     Document Type: Review

References (20)

1. Gheorghiade M, Van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556-2564.
2. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bo?hm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, on behalf of the ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
3. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
4. Camm AJ, Kirchof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Goronek B, heldal M, Hohnloser SH, Kolh P, Le Heuzey JY, Ponikowksi P, Rutten FH, on behalf of the ESC Guidelines for the management of atrial fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-2429.
5. Van Veldhuisen DJ, De Graeff PA, Remme WJ, Lie KI. Value of digoxin in heart failure and sinus rhythm: new features of an old drug? J Am Coll Cardiol 1996; 28:813-819.
6. Gheorghiade M, Ferguson D. Digoxin: a neurohormonal modulator in heart failure? Circulation 1991;84:2181-2186.
7. Van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PJGM, Lok DJA, Dohmen HJM, Poortermans JC, Withagen AJAM, Pasteuning WH, Brouwer J, Lie KI, on behalf of the DIMT Study Group. Double-blind, placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993;22:1564-1573.
8. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27:178-186.
9. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871-878.
10. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JGF. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944-1951.
11. Friberg L, Hammar N, Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart 2010;96:275-280.
12. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrel VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients taking digoxin - analysis from the AFFIRM study. Eur Heart J 2013;34:1481-1488.
13. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
14. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1509-1513.
15. Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis - a new controversy regarding and old drug. The pitfalls of inappropriate methods. Circulation 1986;73:14-18.
16. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van Den Berg MP. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
17. Rienstra MR, Damman K, Mulder BA, Van Gelder IC, McMurray JJV, Van Veldhuisen DJ. Beta-blockers in patients with heart failure and atrial fibrillation. A meta-analysis. J Am Coll Cardiol HF 2013;1:21-28.
18. Van Veldhuisen DJ. Low-dose digoxin in patients with heart failure: less toxic and at least as effective? J Am Coll Cardiol 2002;39:954-956
19. Castagno D, Petrie MC, Claggett B, McMurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012;33:1137-1141
20. Cohn JN. Inotropic therapy for heart failure: paradise lost. Eur Heart J 2009; 30:2965-2966